Weill Scientists Reach New Heights With Multiple Sclerosis Drug Treatment

On Feb. 8, a new study on the multiple sclerosis drug siponimod conducted by researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center was published in Nature Communications. The study analyzed the drug’s shape and interactions in the body, allowing researchers to understand how to lessen the drug’s side effects, such as heart and liver problems, during treatment for MS patients.